ITGAM and acute myeloid leukemia: It has also been shown that CD33+CD11b+HLA-DR−/low MDSCs accumulate in the BM of AML patients and their presence may have an impact on disease prognosis and patients’ clinical course.21 Furthermore, MDSCs levels in newly diagnosed AML patients have been reported to correlate with AML subtype, presence of chromosomal abnormalities and gene alterations, extramedullary involvement, and plasma D-dimer levels.